The 2020 transcripts of 241 pharmaceutical companies are released!

Medical Network News, March 1 With the intensive disclosure of the performance of listed companies in the 2020 annual report, the transcripts of pharmaceutical companies have gradually surfaced.
Up to now, a total of 241 pharmaceutical companies in A-shares have disclosed their performance, over 60% of which are pre-happy, and 74 companies have doubled their net profits.
12 companies including Mindray Medical, Zhifei Biotechnology, Changchun High-tech and WuXi AppTec are expected to have net profits exceeding 2 billion yuan.
Eight companies including Yiling Pharmaceutical, Dashenlin, Tigermed, Kanglong Chemical have exceeded 1 billion for the first time.
turn off.
In addition, 44 pharmaceutical companies lost money.
Among them, 8 companies including ST Tiansheng, Frontier Biotech, Kangsino, and Junshi Biotechnology increased their losses, and 16 companies including Jincheng Pharmaceutical and Zixin Pharmaceutical lost the first time.

 

2020 performance of A-share pharmaceutical companies

 

A-share pharmaceutical companies' 2020 performance report

 

2020 performance forecast of A-share pharmaceutical companies

 

The net profit of 12 companies exceeded 2 billion! Yiling, Dashenlin.
.
.
8 companies have entered the 1 billion echelon

 

Judging from the disclosed performance in 2020, more than 60% of the pre-happy.
Among them, 12 companies including Zhifei Biotechnology, Changchun High-tech, WuXi AppTec are expected to have a net profit of over 2 billion yuan.
Eight companies including Yiling Pharmaceutical, Dashenlin, Tigermed, Kanglong Chemical have exceeded 1 billion for the first time.
turn off.

 

　　Zhifei Biology: According to the company's performance bulletin, in 2020, it will realize operating income of 15.
19 billion yuan, a year-on-year increase of 43.
48%; net profit of 3.
3 billion yuan, a year-on-year increase of 39.
47%.
Zhifei said that in 2020, the new crown epidemic will break out, and the efficiency of logistics and transportation, the flow of personnel, and the development of vaccination clinics have undergone major changes compared with the same period last year.
Despite the adverse effects of the epidemic, the company has actively engaged in anti-epidemic work, steadily promoted the resumption of work and production, and strived to do a good job in the management of research, production and sales, and continued to focus on the research and development, production, sales, promotion, distribution, and imported vaccine pharmnet.
com.
cn/agent_product/" target="_blank">agents of vaccines and biological products .
The business development momentum is good, and the sales of vaccine products have grown steadily, which promoted the steady improvement of the company's performance.

 

　　Yiling Pharmaceutical: Net profit is expected to increase by 90% to 110% year-on-year in 2020, breaking through the 1 billion mark.
Regarding the substantial growth in performance, Yiling Pharmaceutical said that on the one hand, the brand awareness of the company's Lianhua Qingwen products has been greatly improved, the domestic market demand has increased significantly, and sales have also been achieved in more than ten registered overseas countries.
The sales revenue of Qingwen products achieved rapid growth compared with the same period in 2019.
On the other hand, in January 2020, the company won the first prize of the National Science and Technology Progress Award, and its effect on the market influence of the company's cardio-cerebrovascular products has been initially revealed.
The company's cardio-cerebrovascular product sales revenue has increased year-on-year.
According to data, in the first three quarters of 2020, Lianhua Qingwen products achieved operating income of 2.
871 billion yuan, accounting for 44.
52% of the company's total operating income.
In January of this year, Lianhua Qingwen Capsules received drug registration approvals from Mongolia and Uzbekistan.
Up to now, Lianhua Qingwen Capsules have been used in Hong Kong, Macau, Brazil, Indonesia, Canada, Mozambique, Romania, Thailand, and China.
More than 10 countries and regions, including Ecuador and Singapore, have registered and obtained marketing authorizations as Chinese patent medicines, pharmaceuticals , botanicals, natural health products, and natural medicines.

 

　　Dashenlin: It is estimated that the net profit in 2020 will exceed the 1 billion mark, an increase of 50% to 60% year-on-year, and the net profit in 2019 will be 703 million yuan.
Da Shenlin said that in the face of the impact of the new crown epidemic, in terms of main business, the company’s management has actively taken various measures to strengthen the prevention and control of the epidemic.
At the same time, it has improved the endogenous growth trend of the old store by optimizing the internal refined management level, and passed The development strategy of “ self-construction + mergers and acquisitions + franchise ” has made every effort to expand the market layout of the provinces, and internal promotion and external expansion ensure the rapid growth of the company's operating performance.
In terms of operating costs, in order to deepen the development of the human resource system to ensure the need for strategic expansion, the annual increase in performance incentives, employee equity incentives and other measures to increase the cost of investment to enhance the attractiveness of market talents.
In addition, the increase in non-operating profit and loss was mainly due to the increase in bank financial management income, government subsidies, non-operating income and expenditures.

 

　　44 pharmaceutical companies lose money! 16 companies lost the first time, 8 companies increased their losses

 

　　Up to now, 44 pharmaceutical companies are expected to lose net profits.
Among them, 8 companies including ST Tiansheng, Frontier Biotech, Kangsino, and Junshi Biotech have increased their losses, and 16 companies including Jincheng Pharmaceutical, Zixin Pharmaceutical, and Shuangcheng Pharmaceutical have increased their losses.
deficit.

 

　　Jincheng Pharmaceutical: It is estimated that the net profit for the first time in 2020 will be 450 million to 500 million yuan, a year-on-year decrease of 321.
36% to 345.
96%, and the net profit in the first three quarters of 2020 will be 208 million yuan.
Regarding the “changing face” of performance, Jincheng Pharmaceutical pointed out in the announcement that on the one hand, the company’s wholly-owned subsidiaries Jincheng Taier and Jincheng Suzhi showed signs of impairment.
After preliminary calculations, it plans to withdraw a total of 742 million yuan for goodwill impairment.
After the accrual, the goodwill balances of Jinchengtaier and Jincheng Suzhi are both 0.
On the other hand, due to factors such as pharmaceutical industry policies and the epidemic, Jinchengtaier in the preparations sector has experienced a decline in sales, increased sales and R&D expenses, and a loss in performance.
Cefixime active ester products in the pharmaceutical intermediates sector are mainly exported to the Indian market.
In 2020, affected by the Indian epidemic, the sales and prices of this product have fallen year-on-year, which will have a certain impact on the performance of the pharmaceutical and chemical sector.
In addition, the company's export business was affected by the depreciation of the US dollar in the foreign exchange market, leading to increased exchange losses.

 

　　Zixin Pharmaceutical: At the end of January this year, Zixin Pharmaceutical issued a revised announcement on its 2020 performance forecast.
Before the revision, the net profit loss for 2020 is expected to be 300 million to 350 million yuan, a year-on-year decrease of 526.
80% to 597.
94%; after the revision, the net loss is expected 590-690 million yuan, a year-on-year decrease of 939.
38% to 1081.
65%.
Regarding the reasons for the performance revision, Zixin Pharmaceutical said that after the company and its subsidiaries have conducted a comprehensive inventory of various assets and asset impairment tests at the end of 2020, they will accrue provisions for inventories, intangible assets, and fixed assets that have signs of impairment.
The corresponding impairment provision.
In 2020, it is planned to withdraw 294 million yuan for asset impairment, which will be included in the company's 2020 profit and loss, which will reduce the company's 2020 net profit by 258 million yuan.

 

　　Source: Oriental Fortune.
com, Announcement of Listed Companies

　　Medical Network News, March 1 With the intensive disclosure of the performance of listed companies in the 2020 annual report, the transcripts of pharmaceutical companies have gradually surfaced.
Up to now, a total of 241 pharmaceutical companies in A-shares have disclosed their performance, over 60% of which are pre-happy, and 74 companies have doubled their net profits.
12 companies including Mindray Medical, Zhifei Biotechnology, Changchun High-tech and WuXi AppTec are expected to have net profits exceeding 2 billion yuan.
Eight companies including Yiling Pharmaceutical, Dashenlin, Tigermed, Kanglong Chemical have exceeded 1 billion for the first time.
turn off.
In addition, 44 pharmaceutical companies lost money.
Among them, 8 companies including ST Tiansheng, Frontier Biotech, Kangsino, and Junshi Biotechnology increased their losses, and 16 companies including Jincheng Pharmaceutical and Zixin Pharmaceutical lost the first time.

 

　　2020 performance of A-share pharmaceutical companies

 

　　A-share pharmaceutical companies' 2020 performance report

 

　　2020 performance forecast of A-share pharmaceutical companies

 

　　The net profit of 12 companies exceeded 2 billion! Yiling, Dashenlin.
.
.
8 companies have entered the 1 billion echelon

 

　　Judging from the disclosed performance in 2020, more than 60% of the pre-happy.
Among them, 12 companies including Zhifei Biotechnology, Changchun High-tech, WuXi AppTec are expected to have a net profit of over 2 billion yuan.
Eight companies including Yiling Pharmaceutical, Dashenlin, Tigermed, Kanglong Chemical have exceeded 1 billion for the first time.
turn off.

 

　　Zhifei Biology: According to the company's performance bulletin, in 2020, it will realize operating income of 15.
19 billion yuan, a year-on-year increase of 43.
48%; net profit of 3.
3 billion yuan, a year-on-year increase of 39.
47%.
Zhifei said that in 2020, the new crown epidemic will break out, and the efficiency of logistics and transportation, the flow of personnel, and the development of vaccination clinics have undergone major changes compared with the same period last year.
Despite the adverse effects of the epidemic, the company has actively engaged in anti-epidemic work, steadily promoted the resumption of work and production, and strived to do a good job in the management of research, production and sales, and continued to focus on the research and development, production, sales, promotion, distribution, and imported vaccine pharmnet.
com.
cn/agent_product/" target="_blank">agents of vaccines and biological products .
The business development momentum is good, and the sales of vaccine products have grown steadily, which promoted the steady improvement of the company's performance.

 

　　Yiling Pharmaceutical: Net profit is expected to increase by 90% to 110% year-on-year in 2020, breaking through the 1 billion mark.
Regarding the substantial growth in performance, Yiling Pharmaceutical said that on the one hand, the brand awareness of the company's Lianhua Qingwen products has been greatly improved, the domestic market demand has increased significantly, and sales have also been achieved in more than ten registered overseas countries.
The sales revenue of Qingwen products achieved rapid growth compared with the same period in 2019.
On the other hand, in January 2020, the company won the first prize of the National Science and Technology Progress Award, and its effect on the market influence of the company's cardio-cerebrovascular products has been initially revealed.
The company's cardio-cerebrovascular product sales revenue has increased year-on-year.
According to data, in the first three quarters of 2020, Lianhua Qingwen products achieved operating income of 2.
871 billion yuan, accounting for 44.
52% of the company's total operating income.
In January of this year, Lianhua Qingwen Capsules received drug registration approvals from Mongolia and Uzbekistan.
Up to now, Lianhua Qingwen Capsules have been used in Hong Kong, Macau, Brazil, Indonesia, Canada, Mozambique, Romania, Thailand, and China.
More than 10 countries and regions, including Ecuador and Singapore, have registered and obtained marketing authorizations as Chinese patent medicines, pharmaceuticals , botanicals, natural health products, and natural medicines.

 

　　Dashenlin: It is estimated that the net profit in 2020 will exceed the 1 billion mark, an increase of 50% to 60% year-on-year, and the net profit in 2019 will be 703 million yuan.
Da Shenlin said that in the face of the impact of the new crown epidemic, in terms of main business, the company’s management has actively taken various measures to strengthen the prevention and control of the epidemic.
At the same time, it has improved the endogenous growth trend of the old store by optimizing the internal refined management level, and passed The development strategy of “ self-construction + mergers and acquisitions + franchise ” has made every effort to expand the market layout of the provinces, and internal promotion and external expansion ensure the rapid growth of the company's operating performance.
In terms of operating costs, in order to deepen the development of the human resource system to ensure the need for strategic expansion, the annual increase in performance incentives, employee equity incentives and other measures to increase the cost of investment to enhance the attractiveness of market talents.
In addition, the increase in non-operating profit and loss was mainly due to the increase in bank financial management income, government subsidies, non-operating income and expenditures.

 

　　44 pharmaceutical companies lose money! 16 companies lost the first time, 8 companies increased their losses

 

　　Up to now, 44 pharmaceutical companies are expected to lose net profits.
Among them, 8 companies including ST Tiansheng, Frontier Biotech, Kangsino, and Junshi Biotech have increased their losses, and 16 companies including Jincheng Pharmaceutical, Zixin Pharmaceutical, and Shuangcheng Pharmaceutical have increased their losses.
deficit.

 

　　Jincheng Pharmaceutical: It is estimated that the net profit for the first time in 2020 will be 450 million to 500 million yuan, a year-on-year decrease of 321.
36% to 345.
96%, and the net profit in the first three quarters of 2020 will be 208 million yuan.
Regarding the “changing face” of performance, Jincheng Pharmaceutical pointed out in the announcement that on the one hand, the company’s wholly-owned subsidiaries Jincheng Taier and Jincheng Suzhi showed signs of impairment.
After preliminary calculations, it plans to withdraw a total of 742 million yuan for goodwill impairment.
After the accrual, the goodwill balances of Jinchengtaier and Jincheng Suzhi are both 0.
On the other hand, due to factors such as pharmaceutical industry policies and the epidemic, Jinchengtaier in the preparations sector has experienced a decline in sales, increased sales and R&D expenses, and a loss in performance.
Cefixime active ester products in the pharmaceutical intermediates sector are mainly exported to the Indian market.
In 2020, affected by the Indian epidemic, the sales and prices of this product have fallen year-on-year, which will have a certain impact on the performance of the pharmaceutical and chemical sector.
In addition, the company's export business was affected by the depreciation of the US dollar in the foreign exchange market, leading to increased exchange losses.

 

　　Zixin Pharmaceutical: At the end of January this year, Zixin Pharmaceutical issued a revised announcement on its 2020 performance forecast.
Before the revision, the net profit loss for 2020 is expected to be 300 million to 350 million yuan, a year-on-year decrease of 526.
80% to 597.
94%; after the revision, the net loss is expected 590-690 million yuan, a year-on-year decrease of 939.
38% to 1081.
65%.
Regarding the reasons for the performance revision, Zixin Pharmaceutical said that after the company and its subsidiaries have conducted a comprehensive inventory of various assets and asset impairment tests at the end of 2020, they will accrue provisions for inventories, intangible assets, and fixed assets that have signs of impairment.
The corresponding impairment provision.
In 2020, it is planned to withdraw 294 million yuan for asset impairment, which will be included in the company's 2020 profit and loss, which will reduce the company's 2020 net profit by 258 million yuan.

 

　　Source: Oriental Fortune.
com, Announcement of Listed Companies